Bayer Pharma AG

Essence of this Article

The oral, direct Factor Xa inhibitor betrixaban has been investigated for the prevention of venous thromboembolism (VTE) after orthopaedic surgery. The phase II EXPERT study randomized patients undergoing elective total knee replacement surgery to receive betrixaban 15 mg or 40 mg twice daily, or enoxaparin 30 mg twice daily, for 10–14 days after surgery. The incidence of VTE was 20% with betrixaban 15 mg twice daily, 15% with betrixaban 40 mg twice daily and 10% with enoxaparin 30 mg twice daily. There was no bleeding with betrixaban 15 mg twice daily and 2% of patients had clinically relevant non-major bleeding with betrixaban 40 mg twice daily. No phase III study of betrixaban is currently underway in orthopaedic surgery.

Investigational strategies for venous thromboembolism prophylaxis

The oral, direct Factor Xa inhibitor betrixaban has been investigated for the prevention of VTE after orthopaedic surgery. The phase II EXPERT study randomized patients undergoing elective total knee replacement surgery to receive betrixaban 15 mg or 40 mg twice daily, or enoxaparin 30 mg twice daily, for 10–14 days after surgery.116 The incidence of VTE was 20% with betrixaban 15 mg twice daily, 15% with betrixaban 40 mg twice daily and 10% with enoxaparin 30 mg twice daily.116 There was no bleeding with betrixaban 15 mg twice daily and 2.4% of patients had clinically relevant non-major bleeding with betrixaban 40 mg twice daily.116 No phase III study of betrixaban in orthopaedic surgery is currently underway. Learn more about ongoing studies in acutely ill medical patients here.


Where to next?